2026-06-18T05:38:28Zhttps://riubu.ubu.es/oai/request

oai:riubu.ubu.es:10259/88202024-03-15T01:05:13Zcom_10259_4219com_10259_5086com_10259_2604col_10259_4220

Kovács, Norbert Bergmann, Lars Anca-Herschkovitsch, Marieta Cubo Delgado, Esther Davis, Thomas L. Iansek, Robert Siddiqui, Mustafa S. Simu, Mihaela Standaert, David G. Chaudhuri, K. Ray Bourgeois, Paul Gao, Tianming Kukreja, Pavnit Pontieri, Francesco E. Aldred, Jason 2024-03-14T11:01:55Z 2024-03-14T11:01:55Z 2022-04 1877-7171 http://hdl.handle.net/10259/8820 10.3233/JPD-212979 1877-718X Background: It is believed that motor symptoms, including dyskinesia, and non-motor symptoms impact health-related quality of life (HRQoL) in patients with Parkinson’s disease (PD), and that improvements in these metrics are correlated. Objective: Investigate the relationship between HRQoL and measures of PD severity and treatment efficacy, including motor and non-motor symptoms. Methods: This was a planned investigation of an international, prospective, single-arm, post-marketing observational study of the long-term effectiveness of levodopa-carbidopa intestinal gel (LCIG) in patients with advanced PD. Pearson correlation coefficients (PCC) were calculated for baseline and change from baseline at 12 months between HRQoL and motor and non-motor symptoms. Results: A total of 195 patients were included. At baseline, HRQoL was moderately positively correlated with Activities of Daily Living (UPDRS II, PCC = 0.44), non-motor symptoms (0.48), and measures of sleep (0.50 and 0.40); all p < 0.001. After 12 months of treatment with LCIG, improvements in HRQoL were moderately positively correlated with improvement from baseline in non-motor symptoms (PCC = 0.42), sleep (0.54), and daytime sleepiness (0.40; all p < 0.001), and weakly correlated with improvement in dyskinesia signs and symptoms (PCC = 0.23; p = 0.011). Improvement in HRQoL was not correlated with improvements in OFF time or dyskinesia time. Conclusion: Both at baseline and for change from baseline at 12 months, HRQoL was correlated with baseline and change from baseline in dyskinesia, Activities of Daily Living, and non-motor symptoms, including sleep; but not with baseline or change in OFF time. eng IOS Press Journal of Parkinson's Disease. 2022, V. 12, n. 3, p. 917-926 https://content.iospress.com/articles/journal-of-parkinsons-disease/jpd212979 Atribución 4.0 Internacional http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Dyskinesia Health-related quality of life Levodopa-carbidopa intestinal gel Non-motor symptoms Parkinson’s disease Sistema nervioso-Enfermedades Medicina Neurología Nervous system-Diseases Medicine Neurology Outcomes Impacting Quality of Life in Advanced Parkinson’s Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Journal of Parkinson's Disease 12 3 917 926